Shopping Cart 0
Cart Subtotal
USD 0

Genzyme Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty care treatments targeting rare diseases, oncology, immunology and multiple sclerosis. It offers products for the treatment of indications including various forms of cancer, mucopolysaccharidosis I, multiple sclerosis, Gaucher disease type 1, long-term enzyme replacement therapy, acute lymphoblastic leukemia, atopic dermatitis, management of uric acid levels, fabry disease, rheumatoid arthritis, Pompe disease, non-Hodgkin's lymphoma, multiple myleoma, gastric adenocarcinoma and squamous cell carcinoma, and kidney transplant acute rejection. The company has several more products in various stages of development. It operates a research and development lab and manufacturing plants in the US, Belgium and Ireland. The company has presence across the world. Genzyme is headquartered in Massachusetts, the US.

Genzyme Corp-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10

Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Genzyme Corp, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Genzyme Acquires Caprelsa from AstraZeneca 13

Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 14

Venture Financing 15

Edimer Pharma Secures USD18 Million in Series B Funding 15

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 16

Partnerships 18

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 18

Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 19

Recursion Pharma Enters into Research Agreement with Genzyme 20

Ablynx Enters into Research Agreement with Genzyme 21

Voyager Therapeutics Enters into Development Agreement with Genzyme 22

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 23

Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 24

Genzyme Enters Into Research Agreement With Cleveland Clinic 25

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 26

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 28

Merger 29

Sanofi Japan and Genzyme Japan Merge 29

Licensing Agreements 30

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 30

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 31

Equity Offering 32

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 32

KaloBios Pharma Completes IPO For USD 70 Million 33

Asset Transactions 36

Admedus Acquires Manufacturing Facility From Genzyme Australasia 36

Genzyme Corp-Key Competitors 37

Genzyme Corp-Key Employees 38

Genzyme Corp-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Joint Venture 41

Recent Developments 42

Clinical Trials 42

Apr 11, 2017: Sanofi Genzyme to present data on GLD52 (GZ402668) at AAN 42

Feb 14, 2017: Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson's Disease 43

Other Significant Developments 44

Mar 22, 2017: Sanofi Genzyme Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcomes Through Peer-to-Peer Education 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Genzyme Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genzyme Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Genzyme Corp, Pharmaceuticals & Healthcare, Key Facts 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genzyme Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10

Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Genzyme Acquires Caprelsa from AstraZeneca 13

Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 14

Edimer Pharma Secures USD18 Million in Series B Funding 15

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 16

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 18

Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 19

Recursion Pharma Enters into Research Agreement with Genzyme 20

Ablynx Enters into Research Agreement with Genzyme 21

Voyager Therapeutics Enters into Development Agreement with Genzyme 22

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 23

Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 24

Genzyme Enters Into Research Agreement With Cleveland Clinic 25

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 26

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 28

Sanofi Japan and Genzyme Japan Merge 29

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 30

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 31

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 32

KaloBios Pharma Completes IPO For USD 70 Million 33

Admedus Acquires Manufacturing Facility From Genzyme Australasia 36

Genzyme Corp, Key Competitors 37

Genzyme Corp, Key Employees 38

Genzyme Corp, Other Locations 39

Genzyme Corp, Subsidiaries 39

Genzyme Corp, Joint Venture 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Genzyme Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty care treatments targeting rare diseases, oncology, immunology and multiple sclerosis. It offers products for the treatment of indications including various forms of cancer, mucopolysaccharidosis I, multiple sclerosis, Gaucher disease type 1, long-term enzyme replacement therapy, acute lymphoblastic leukemia, atopic dermatitis, management of uric acid levels, fabry disease, rheumatoid arthritis, Pompe disease, non-Hodgkin's lymphoma, multiple myleoma, gastric adenocarcinoma and squamous cell carcinoma, and kidney transplant acute rejection. The company has several more products in various stages of development. It operates a research and development lab and manufacturing plants in the US, Belgium and Ireland. The company has presence across the world. Genzyme is headquartered in Massachusetts, the US.

Genzyme Corp-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10

Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Genzyme Corp, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Genzyme Acquires Caprelsa from AstraZeneca 13

Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 14

Venture Financing 15

Edimer Pharma Secures USD18 Million in Series B Funding 15

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 16

Partnerships 18

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 18

Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 19

Recursion Pharma Enters into Research Agreement with Genzyme 20

Ablynx Enters into Research Agreement with Genzyme 21

Voyager Therapeutics Enters into Development Agreement with Genzyme 22

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 23

Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 24

Genzyme Enters Into Research Agreement With Cleveland Clinic 25

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 26

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 28

Merger 29

Sanofi Japan and Genzyme Japan Merge 29

Licensing Agreements 30

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 30

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 31

Equity Offering 32

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 32

KaloBios Pharma Completes IPO For USD 70 Million 33

Asset Transactions 36

Admedus Acquires Manufacturing Facility From Genzyme Australasia 36

Genzyme Corp-Key Competitors 37

Genzyme Corp-Key Employees 38

Genzyme Corp-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Joint Venture 41

Recent Developments 42

Clinical Trials 42

Apr 11, 2017: Sanofi Genzyme to present data on GLD52 (GZ402668) at AAN 42

Feb 14, 2017: Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson's Disease 43

Other Significant Developments 44

Mar 22, 2017: Sanofi Genzyme Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcomes Through Peer-to-Peer Education 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Genzyme Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genzyme Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Genzyme Corp, Pharmaceuticals & Healthcare, Key Facts 2

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genzyme Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10

Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Genzyme Acquires Caprelsa from AstraZeneca 13

Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 14

Edimer Pharma Secures USD18 Million in Series B Funding 15

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 16

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 18

Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 19

Recursion Pharma Enters into Research Agreement with Genzyme 20

Ablynx Enters into Research Agreement with Genzyme 21

Voyager Therapeutics Enters into Development Agreement with Genzyme 22

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 23

Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 24

Genzyme Enters Into Research Agreement With Cleveland Clinic 25

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 26

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 28

Sanofi Japan and Genzyme Japan Merge 29

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 30

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 31

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 32

KaloBios Pharma Completes IPO For USD 70 Million 33

Admedus Acquires Manufacturing Facility From Genzyme Australasia 36

Genzyme Corp, Key Competitors 37

Genzyme Corp, Key Employees 38

Genzyme Corp, Other Locations 39

Genzyme Corp, Subsidiaries 39

Genzyme Corp, Joint Venture 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Genzyme Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.